Navigation Group LLC Takes $1.24 Million Position in Merck & Co., Inc. $MRK

Navigation Group LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 10,265 shares of the company’s stock, valued at approximately $1,235,000.

Other large investors have also recently bought and sold shares of the company. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. during the fourth quarter valued at about $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. High Note Wealth LLC lifted its holdings in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $31,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Up 2.3%

Shares of MRK stock opened at $123.56 on Thursday. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $130.29. The firm has a market cap of $305.16 billion, a PE ratio of 34.80, a price-to-earnings-growth ratio of 3.03 and a beta of 0.19. The stock has a 50 day moving average of $119.48 and a 200-day moving average of $116.72. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter last year, the company posted $2.22 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 4.35 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on MRK shares. Citigroup initiated coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. Scotiabank boosted their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. UBS Group upped their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Sunday. Finally, CICC Research assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.94.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.